Preview

Transbaikalian Medical Bulletin

Advanced search

Insulin resistance and polycystic ovary syndrome: the current state of the problem

https://doi.org/10.52485/19986173_2025_1_171

Abstract

 

Polycystic ovary syndrome (PCOS) is one of the most common pathologies found in women of reproductive age. The article presents a modern view on the problem of the development of PCOS. Insulin resistance (IR) plays an important role in the pathogenesis of this syndrome. An increased concentration of insulin leads to disturbances in the hypothalamic-pituitary-ovarian system, resulting in hyperandrogenemia and anovulation. A number of studies indicate the emergence of a vicious circle between hyperandrogenemia and hyperinsulinemia, which aggravate each other through reciprocal mechanisms. One of the links in the pathogenesis of PCOS development may be oxidative stress, which is associated with damage to cell membranes, disruption of intracellular signaling, which leads to meta-inflammation and subsequent insulin resistance. Studies demonstrating the connection between the intestinal microbiota and insulin resistance deserve special attention. However, there is no clear understanding of what is primary in the pathogenesis – an imbalance of microorganisms in the intestine, which affects the development of PCOS, or, on the contrary, PCOS contributes to the occurrence of an imbalance of intestinal microbiota. Understanding the holistic picture of the mechanism of development of PCOS allows us to identify several vectors of pathogenetic therapy for this disease, among which an important place is occupied by the correction of meta-inflammation, insulin resistance, oxidative stress and normalization of the balance of intestinal microbiota. The presented review demonstrates the validity of these therapeutic priorities.

About the Authors

I. S. Zakharov
Military Medical Academy
Russian Federation

Igor S. Zakharov - Doctor of Medical Sciences, Professor of the Department of Obstetrics and Gynecology, Military Medical Academy.

6 Akademic Lebedev st., Saint Petersburg, 194044

Author ID 231781, Author ID Scopus 57471508300



R. I. Glushakov
Military Medical Academy
Russian Federation

Ruslan I. Glushakov - Doctor of Medical Sciences, Head of the Department of Medical and Biological Research of the Research Center, Military Medical Academy.

6 Akademic Lebedev st., Saint Petersburg, 194044

Author ID 621995, Author ID Scopus 55263592100



V. S. Pankratova
Military Medical Academy
Russian Federation

Valeria S. Pankratova - obstetrician-gynecologist, Military Medical Academy.

6 Akademic Lebedev st., Saint Petersburg, 194044

Author ID 1190281



References

1. Demidova T.Yu., Zenina S.G. Insulin resistance and its role in the development of diabetes and other conditions. Current modalities to improve insulin sensitivity. Russian Medical Journal. 2019. 10(II). 116- 122. in Russian.

2. Zarkhanov T.S., Lozhkina N.G. Metabolomic predictors of cardiovascular complications in newly detected non-small cell lung cancer. Bulletin of Medical Science. 2024. 1(33). 128-135. DOI 10.31684/25418475-2024-1-128. in Russian.

3. Bermudez V., Salazar J., Martínez M.S., et al. Rojas J. Prevalence and Associated Factors of Insulin Resistance in Adults from Maracaibo City, Venezuela. Advances in Preventive Medicine. 2016. 9405105. DOI 10.1155/2016/9405105.

4. Qu H-Q., Li Q., Rentfro A.R., et al. The Definition of Insulin Resistance Using HOMA-IR for Americans of Mexican Descent Using Machine Learning. PLoS ONE. 2011. 6. e21041. DOI 10.1371/journal.pone.0021041.

5. Barsukov I.A., Demina A.A. Obesity and insulin resistance: pathogenesis and ways of correction. Russian Medical Journal. 2021. 2. 26-30. in Russian.

6. Yaribeygi H., Farrokhi F.R., Butler A.E., et al. Insulin resistance: Review of the underlying molecular mechanisms. Journal of Cellular Physiology. 2019. 234. 8152-8161. DOI 10.1002/jcp.27603.

7. Barazzoni R., Cappellari G.G., Ragni M., et al. Insulin resistance in obesity: an overview of fundamental alterations. Eat Weight Disorders. 2018. 23. 149-157. DOI 10.1053/j.jrn.2007.10.015.

8. Romantsova T.R., Sych Yu.P. Immunometabolism and metainflammation in obesity. Obesity and metabolism. 2019. 16(4). 3-17. DOI 10.14341/omet12218. in Russian.

9. Osegbe I., Okpara H., Azinge E. Relationship between serum leptin and insulin resistance among obese Nigerian women. Annals of African Medicine. 2016. 15(1). 14-19. DOI 10.4103/1596-3519.158524.

10. Von Eynatten M., Hamann A., Twardella D., et al. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clinical Chemistry. 2006. 52(5). 853-859. DOI 10.1373/clinchem.2005.060509.

11. Andreeva E.N., Pishchulin A.A., Akmaev R.I., et al. A comparative study of the effect of insulin resistance on androgenic activity of the adrenal glands and ovaries in women of early reproductive age with polycystic ovary syndrome. Obesity and metabolism. 2010. 7(2). 29-35. DOI 10.14341/2071-8713-5206. in Russian.

12. Taits A.N., Vorobtsova I.N., Kurdynko L.V., et al. Pathophysiological aspects of the formation of insulin resistance in women with polycystic ovary syndrome. Medicine: theory and practice. 2020. 3(2). 19-25. in Russian.

13. Capllonch-Amer G., Lladó I., Proenza A.M., García-Palmer F.J., et al. Opposite effects of 17-β estradiol and testosterone on mitochondrial biogenesis and adiponectin synthesis in white adipocytes. The Journal of Molecular Endocrinology. 2014. 52. 203-214. DOI 10.1530/JME-13-0201.

14. Yan H., Wang L., Zhang G. Oxidative stress and energy metabolism abnormalities in polycystic ovary syndrome: from mechanisms to therapeutic strategies. Reprod Biol Endocrinol. 2024. 22(1). 159. DOI 10.1186/s12958-024-01337-0.

15. Zakharov I.S., Bukreeva E.L. Oxidative stress in the syndrome of polycystic ovaries: prognostic value, correction possibilities. Gynecology. 2018. 20(1). 35-38. DOI 10.26442/2079-5696_20.1.35-38. in Russian.

16. Phielix E., Szendroedi J., Roden M. Mitochondrial function and insulin resistance during aging: a minireview. Gerontology. 2011. 57. 387-396. DOI 10.1159/000317691.

17. Özer A., Bakacak M., Kıran H., et al. Increased oxidative stress is associated with insulin resistance and infertility in polycystic ovary syndrome. Ginekologia Polska. 2016. 87(11). 733-738. DOI 10.5603/GP.2016.0079.

18. Onyango A.N. The Contribution of Singlet Oxygen to Insulin Resistance. Oxidative Medicine and Cellular Longevity. 2017. 8765972. DOI 10.1155/2017/8765972.

19. Rojo M., Pérez H., Millán AL. et al. Mitochondrial DNA oxidation and content in different metabolic phenotypes of women with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2025. 15. 1501306. DOI 10.3389/fendo.2024.1501306.

20. Mishenko O.I., Mozes V.G., Kosinova M.V., et al. Gestational diabetes mellitus – modern representations on epidemiology, pathogenesis, diagnostics and prevention of complications. The Transbaikalian Medical Bulletin. 2020. 1. 111-120. DOI 10.52485/19986173_2020_1_111. in Russian.

21. Magne F., Gotteland M., Gauthier L., et al., Balamurugan R. The Firmicutes/Bacteroidetes ratio: a relevant marker of gut dysbiosis in obese patients? Nutrients. 2020. 12(5). 1474. DOI 10.3390/nu12051474.

22. Onyango A.N. Cellular Stresses and Stress Responses in the Pathogenesis of InsulinResistance. Oxidative Medicine and Cellular Longevity. 2018. 4321714. DOI 10.1155/2018/4321714.

23. Carvalho B.M., Saad M.J. Influence of gut microbiota on subclinical inflammation and insulin resistance. Mediators of inflammation. 2013. 986734. DOI 10.1155/2013/986734.

24. Saad M.J., Santos A., Prada P.O. Linking Gut Microbiota and Inflammation to Obesity and Insulin Resistance. Physiology (Bethesda). 2016. 31(4). 283-293. DOI 10.1152/physiol.00041.2015.

25. Jobira B., Frank D.N., Pyle L., et al. Obese adolescents with PCOS have altered biodiversity and relative abundance in gastrointestinal microbiota. Journal of Clinical Endocrinology & Metabolism. 2020. 105(6). e2134-e2144. DOI 10.1210/clinem/dgz263.

26. Guo J., Shao J., Yang Y., et al. Gut microbiota in patients with polycystic ovary syndrome: a systematic review. Reproductive Sciences. 2021. 29. 69-83. DOI 10.1007/s43032-020-00430-0.

27. Liang Z., Di N., Li L., et al. Gut microbiota alterations reveal potential gut-brain axis changes in polycystic ovary syndrome. Journal of Endocrinological Investigation. 2021. 44(8). 1727-1737. DOI 10.1007/s40618-020-01481-5.

28. Ren X., Wu W., Li Q., et al. Different supplements improve insulin resistance, hormonal functions, and oxidative stress on overweight and obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2024. 15. 1464959. DOI 10.3389/fendo.2024.1464959.

29. Lim S.S., Hutchison S.K., Van Ryswyk E., et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews. 2019. 3(3). CD007506. DOI 10.1002/14651858.CD007506.pub4.

30. Morley L.C., Tang T., Yasmin E., et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database of Systematic Reviews. 2017. 11. CD003053. DOI 10.1002/14651858.CD003053.pub6.

31. Han Y., Li Y., He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reproductive BioMedicine Online. 2019. 39(2). 332-342. DOI 10.1016/j.rbmo.2019.04.017.

32. Berg V.O., Semenyuk T.G., Vdovin V.M. An evidence-based perspective on the correction of metabolic syndrome with vitamins. Literature review. Bulletin of Medical Science. 2024. 3(35). 114-122. DOI 10.31684/25418475-2024-3-114. in Russian.

33. Yelgina S.I., Zakharov I.S., Rudaeva E.V. Women's reproductive health and features of eating behavior. Fundamental and Clinical Medicine. 2019. 4(3). 48-53. DOI 10.23946/2500-0764-2019-4-3-48-53. in Russian.

34. Forslund K., Hildebrand F., Nielsen T., et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015. 528(7581). 262-266.

35. Chernukha G.E., Udovichenko M.A., Naydukova A.A. Mechanisms of Insulin Resistance Formation in Polycystic Ovarian Disease and Therapeutic Effects from Myo Inositol. Doctor.Ru. 2019. 11(166). 55-60. DOI 10.31550/1727-2378-2019-166-11-55-60. in Russian.

36. Greff D., Juhász A.E., Váncsa S., et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2023. 21(1). 10. DOI: 10.1186/s12958-023-01055-z.

37. Álvarez-Arraño V., Martín-Peláez S. Effects of Probiotics and Synbiotics on Weight Loss in Subjects with Overweight or Obesity: A Systematic Review. Nutrients. 2021. 13(10). 3627. DOI: 10.3390/nu13103627.

38. Zhang F., Ma T., Cui P., et al. Diversity of the gut microbiota in dihydrotestosterone – induced PCOS rats and the pharmacologic effects of Diane-35, probiotics, and berberine. Frontiers in Microbiology. 2019. 10. 175. DOI 10.3389/fmicb.2019.00175.

39. Chernukha G.E., Miroshina E.D., Priputnevich T.V. Polycystic ovary syndrome and intestinal microbiota. Obstetrics and gynecology. 2021. 3. 36-43. DOI 10.18565/aig.2021.3.36-43. in Russian.

40. Sanders M.E., Merenstein D.J., Reid G., et al. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019. 16(10). 605-616. DOI: 10.1038/s41575-019-0173-3.


Supplementary files

Review

For citations:


Zakharov I.S., Glushakov R.I., Pankratova V.S. Insulin resistance and polycystic ovary syndrome: the current state of the problem. Transbaikalian Medical Bulletin. 2025;(1):171-182. (In Russ.) https://doi.org/10.52485/19986173_2025_1_171

Views: 120


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1998-6173 (Online)